Cargando…

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations

INTRODUCTION: In this study, we sought to further characterize ROS1 protein expression in solid tumors with the complete spectrum of ROS1 genomic alterations. METHODS: ROS1 immunohistochemistry (IHC) was performed using the ROS1 (SP384) class I assay per manufacturer’s instructions on a variety of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Richard S.P., Gottberg-Williams, Amanda, Vang, Panhia, Yang, Shoua, Britt, Nicholas, Kaur, Jaspreet, Haberberger, James, Danziger, Natalie, Owens, Clarence, Beckloff, Sara E., Ross, Jeffrey S., Ramkissoon, Shakti H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474213/ https://www.ncbi.nlm.nih.gov/pubmed/34589979 http://dx.doi.org/10.1016/j.jtocrr.2020.100100

Ejemplares similares

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
por: Lin, Jessica J., et al.
Publicado: (2020)

ROS1 amplification mediates resistance to gefitinib in glioblastoma cells
por: Aljohani, Hashim, et al.
Publicado: (2015)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing
por: Zhu, You‐cai, et al.
Publicado: (2018)

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
por: Sievers, Philipp, et al.
Publicado: (2021)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion
por: Liu, Stephen V., et al.
Publicado: (2017)

Clinical, Morphologic and Genomic Findings in ROS1 Fusion Spitz Neoplasms.
por: Gerami, Pedram, et al.
Publicado: (2020)

Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer
por: Yang, Jiangping, et al.
Publicado: (2021)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma
por: Marks, Eric I., et al.
Publicado: (2019)

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
por: Gendarme, Sébastien, et al.
Publicado: (2022)

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
por: He, Yueming, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

Importance of ROS1 gene fusions in non-small cell lung cancer
por: Muminovic, Meri, et al.
Publicado: (2023)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

ROS and ROS-Mediated Cellular Signaling
por: Zhang, Jixiang, et al.
Publicado: (2016)

Microvesicles: ROS scavengers and ROS producers
por: Bodega, G., et al.
Publicado: (2019)

HGG-48. ROS1 INHIBITOR ENTRECTINIB USE IN RELAPSE/REFRACTORY INFANTILE GLIOBLASTOMA WITH POSITIVE ROS1 FUSION - A CASE REPORT WITH PROMISING RESPONSE
por: Ku, Dennis Tak-Loi, et al.
Publicado: (2020)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Wu, Chi‐Hao, et al.
Publicado: (2021)

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
por: Xu, Long, et al.
Publicado: (2021)

ROS amplification drives mouse spermatogonial stem cell self-renewal
por: Morimoto, Hiroko, et al.
Publicado: (2019)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
por: Cai, Liangliang, et al.
Publicado: (2020)

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma
por: Lan, Shaowei, et al.
Publicado: (2020)

Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma
por: Das, Arabinda, et al.
Publicado: (2015)

Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Refractory periungual stage II mycosis fungoides with novel LMNA-ROS1 fusion
por: DeRosa, Peter A., et al.
Publicado: (2020)

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Addendum: ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma
por: Marks, Eric I., et al.
Publicado: (2023)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression
por: Peters, Tara L., et al.
Publicado: (2023)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion
por: Furugaki, Koh, et al.
Publicado: (2019)

Caveolin-1 controls mitochondrial damage and ROS production by regulating fission - fusion dynamics and mitophagy
por: Jiang, Ying, et al.
Publicado: (2022)

Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report
por: Wang, Jinjing, et al.
Publicado: (2021)

HGG-23. The presence ofROS1 fusions are not limited only to infantile hemispheric glioma.
por: Trubicka, Joanna, et al.
Publicado: (2022)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
por: Dai, Yinghuan, et al.
Publicado: (2022)

Detection of ROS1 gene fusions using next-generation sequencing for patients with malignancy in China
por: Li, Ning, et al.
Publicado: (2022)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma
por: Cao, Jun, et al.
Publicado: (2022)

ROS and COVID
por: Vardakas, Periklis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qo2gpcml6518m7b7ihhe99dmsp